Free Trial
NASDAQ:BGLC

BioNexus Gene Lab (BGLC) Stock Price, News & Analysis

$0.53
+0.01 (+1.21%)
(As of 03:43 PM ET)
Today's Range
$0.52
$0.55
50-Day Range
$0.52
$0.85
52-Week Range
$0.31
$17.88
Volume
27,890 shs
Average Volume
981,621 shs
Market Capitalization
$9.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BGLC stock logo

About BioNexus Gene Lab Stock (NASDAQ:BGLC)

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

BGLC Stock Price History

BGLC Stock News Headlines

Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today?
BioNexus Gene Lab Invests in AI Healthcare Company
BioNexus Gene Lab Corp Common stock (BGLC)
BGLC BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (BGLC)
Why Is BioNexus Gene Lab (BGLC) Stock Up 33% Today?
BioNexus Gene Lab Corp (BGLC)
BIONEXUS GENE LAB CORP
BioNexus Gene Lab Corp Ordinary Shares
Why Is BioNexus Gene Lab (BGLC) Stock Up 64% Today?
BGLC - BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp.
See More Headlines
Receive BGLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/28/2024
Next Earnings (Estimated)
8/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BGLC
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-2,630,000.00
Pretax Margin
-26.99%

Debt

Sales & Book Value

Annual Sales
$9.77 million
Book Value
$0.55 per share

Miscellaneous

Free Float
16,460,000
Market Cap
$9.30 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Su-Leng Tan (Age 40)
    CEO, Acting CFO, Secretary & Director
    Comp: $16k
  • Mr. Kwan Wah Chan
    Marketing Manager
  • Mr. Too Kam Tham
    Managing Director

BGLC Stock Analysis - Frequently Asked Questions

How have BGLC shares performed in 2024?

BioNexus Gene Lab's stock was trading at $0.53 at the beginning of the year. Since then, BGLC stock has decreased by 0.7% and is now trading at $0.5263.
View the best growth stocks for 2024 here
.

Are investors shorting BioNexus Gene Lab?

BioNexus Gene Lab saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 105,900 shares, a drop of 40.0% from the April 30th total of 176,500 shares. Based on an average daily volume of 218,100 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.3% of the company's stock are short sold.
View BioNexus Gene Lab's Short Interest
.

When is BioNexus Gene Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our BGLC earnings forecast
.

When did BioNexus Gene Lab IPO?

BioNexus Gene Lab (BGLC) raised $5 million in an initial public offering (IPO) on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO.

Who are BioNexus Gene Lab's major shareholders?

BioNexus Gene Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.27%).

How do I buy shares of BioNexus Gene Lab?

Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BGLC) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners